Real-world Associations of US Cystic Fibrosis Newborn Screening Programs with Nutritional and Pulmonary Outcomes
Name:
jamapediatrics_rosenfeld_2022_ ...
Embargo:
2023-08-01
Size:
553.4Kb
Format:
PDF
Description:
Final Published Version
Author
Rosenfeld, M.Ostrenga, J.
Cromwell, E.A.
Magaret, A.
Szczesniak, R.
Fink, A.
Schechter, M.S.
Faro, A.
Ren, C.L.
Morgan, W.
Sanders, D.B.
Issue Date
2022
Metadata
Show full item recordPublisher
American Medical AssociationCitation
Rosenfeld, M., Ostrenga, J., Cromwell, E. A., Magaret, A., Szczesniak, R., Fink, A., Schechter, M. S., Faro, A., Ren, C. L., Morgan, W., & Sanders, D. B. (2022). Real-world Associations of US Cystic Fibrosis Newborn Screening Programs with Nutritional and Pulmonary Outcomes. JAMA Pediatrics.Journal
JAMA PediatricsRights
Copyright © 2022 American Medical Association. All rights reserved.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Importance: Newborn screening (NBS) for cystic fibrosis (CF) has been universal in the US since 2010, but its association with clinical outcomes is unclear. Objective: To describe the real-world effectiveness of NBS programs for CF in the US on outcomes up to age 10 years. Design, Setting, and Participants: This was a retrospective cohort study using CF Foundation Patient Registry data from January 1, 2000, to December 31, 2018. The staggered implementation of NBS programs by state was used to compare longitudinal outcomes among children in the same birth cohort born before vs after the implementation of NBS for CF in their state of birth. Participants included children with an established diagnosis of CF born between January 1, 2000, to December 31, 2018, in any of the 44 states that implemented NBS for CF between 2003 and 2010. Data were analyzed from October 5, 2020, to April 22, 2022. Exposures: Birth before vs after the implementation of NBS for CF in the state of birth. Main Outcomes and Measures: Longitudinal trajectory of height and weight percentiles from diagnosis, lung function (forced expiratory volume in 1 second, [FEV1] percent predicted) from age 6 years, and age at initial and chronic infection with Pseudomonas aeruginosa using linear mixed-effects and time-to-event models adjusting for birth cohort and potential confounders. Results: A total of 9571 participants (4713 female participants [49.2%]) were eligible for inclusion, with 4510 (47.1%) in the pre-NBS cohort. NBS was associated with higher weight and height percentiles in the first year of life (weight, 6.0; 95% CI, 3.1-8.4; height, 6.6; 95% CI, 3.8-9.3), but these differences decreased with age. There was no association between NBS and FEV1at age 6 years, but the percent-predicted FEV1did increase more rapidly with age in the post-NBS cohort. NBS was associated with older age at chronic P aeruginosa infection (hazard ratio, 0.69; 95% CI, 0.54-0.89) but not initial P aeruginosa infection (hazard ratio, 0.88; 95% CI, 0.77-1.01). Conclusions and Relevance: NBS for CF in the US was associated with improved nutritional status up to age 10 years, a more rapid increase in lung function, and delayed chronic P aeruginosa infection. In the future, as highly effective modulator therapies become available for infants with CF, NBS will allow for presymptomatic initiation of these disease-modifying therapies before irreversible organ damage.. © 2022 American Medical Association. All rights reserved.Note
12 month embargo; published online: 01 August 2022ISSN
2168-6203PubMed ID
35913705Version
Final published versionae974a485f413a2113503eed53cd6c53
10.1001/jamapediatrics.2022.2674
Scopus Count
Collections
Related articles
- Impact of newborn screening on outcomes and social inequalities in cystic fibrosis: a UK CF registry-based study.
- Authors: Schlüter DK, Southern KW, Dryden C, Diggle P, Taylor-Robinson D
- Issue date: 2020 Feb
- Effects of Diagnosis by Newborn Screening for Cystic Fibrosis on Weight and Length in the First Year of Life.
- Authors: Leung DH, Heltshe SL, Borowitz D, Gelfond D, Kloster M, Heubi JE, Stalvey M, Ramsey BW, Baby Observational and Nutrition Study (BONUS) Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network
- Issue date: 2017 Jun 1
- Benefits of newborn screening for cystic fibrosis in Shreveport, Louisiana, Cystic Fibrosis Center.
- Authors: Venkata JA, Jones KL
- Issue date: 2011 Nov-Dec
- Outcomes of infants born during the first 9 years of CF newborn screening in the United States: A retrospective Cystic Fibrosis Foundation Patient Registry cohort study.
- Authors: Martiniano SL, Elbert AA, Farrell PM, Ren CL, Sontag MK, Wu R, McColley SA
- Issue date: 2021 Dec
- Differences in Outcomes between Early and Late Diagnosis of Cystic Fibrosis in the Newborn Screening Era.
- Authors: Coffey MJ, Whitaker V, Gentin N, Junek R, Shalhoub C, Nightingale S, Hilton J, Wiley V, Wilcken B, Gaskin KJ, Ooi CY
- Issue date: 2017 Feb